Innovator國際已開發動力緩衝主動型ETF-3月 IMAR 深 滬
已收盤 02-06 16:00:00 美东时间
30.2948
+0.065
+0.22%
華盛通- 最 高30.32
- 今 開30.30
- 成交量 1.46万股
- 最 低 30.27
- 昨 收 30.2297
- 總市值 3408.17万
- 52周最高 30.32
- 市盈率 靜 --
- 換手率 1.30%
- 52周最低 24.6018
- 委 比 -33.33%
- 總股本 112.50万
- 歷史最高 30.32
- 量 比 2.01
- 振 幅 0.17%
- 歷史最低 24.6018
- 每 手 1
- 風險率 1.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lockheed Martin Delivers Additional HIMARS Launchers to Australia
Lockheed Martin Delivers Additional HIMARS Launchers to Australia Lockheed Martin Corporation has reported continued momentum in the delivery of HIMARS launchers to U.S. and partner forces, with more than 750 units provided to date. Australia received its first HIMARS last year, and additional deliv
02-06 07:05
BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial
BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial Feb 3 (Reuters) - Pfizer Inc PFE.N : PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-
02-03 21:21
BRIEF-Exxonmobil Expects Earnings Growth Of $25 Billion Between 2024 & 2030
BRIEF-Exxonmobil Expects Earnings Growth Of $25 Billion Between 2024 & 2030 Jan 30 (Reuters) - Exxon Mobil Corp XOM.N : EXXONMOBIL - ON TRACK TO DELIVER 2030 PLAN, EXPECT ABOUT $25B EARNINGS GROWTH AND ABOUT $35B CASH FLOW GROWTH FROM 2024-2030 - PRESENTATION EXXONMOBIL OUTLOOK Q1 UPSTREAM 100 - 200
01-30 19:58
BRIEF-Sanofi's Amlitelimab Confirms Potential In Atopic Dermatitis
BRIEF-Sanofi's Amlitelimab Confirms Potential In Atopic Dermatitis Jan 23 (Reuters) - Sanofi SA SASY.PA : AMLITELIMAB CONFIRMS ITS POTENTIAL IN ATOPIC DERMATITIS AQUA AND ESTUARY STUDIES TO REPORT RESULTS IN H2 2026 AMLITELIMAB MEETS ALL PRIMARY AND SECONDARY ENDPOINTS IN SHORE STUDY Source text: ID
01-23 14:13
BRIEF-Overall Survival Primary Endpoint Met In Corcept’S Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer
BRIEF-Overall Survival Primary Endpoint Met In Corcept’S Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer Jan 22 (Reuters) - Corcept Therapeutics Inc CORT.O : OVERALL SURVIVAL PRIMARY ENDPOINT MET IN CORCEPT’S PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORIL
01-22 21:19
BRIEF-Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Jan 23 (Reuters) - Larimar Therapeutics Inc LRMR.O: LARIMAR THERAPEUTICS ANNOUNCES DOSING OF ADOLESCENTS IN NOMLABOFUSP PEDIATRIC PHARMACOKINETIC RUN-IN STUDY FOR PATIENTS WITH FRIEDREICH’S ATAXIA LAR...
2025-01-24 06:56
BRIEF-Kantar Group Announces The Proposed Sale Of Kantar Media To H.I.G. Capital
Jan 17 (Reuters) - KANTAR GROUP: ANNOUNCED THE PROPOSED SALE OF KANTAR MEDIA TO H.I.G. CAPITAL KANTAR GROUP: TRANSACTION’S PURCHASE PRICE OF APPROXIMATELY $1 BILLION KANTAR GROUP: DEAL PRICE ANTICIPAT...
2025-01-18 07:21
BRIEF-Omeros Announces Update On Statistical Analysis Of Narsoplimab Pivotal Trial Primary Endpoint
Jan 16 (Reuters) - Omeros Corp OMER.O: OMEROS ANNOUNCES UPDATE ON STATISTICAL ANALYSIS OF NARSOPLIMAB PIVOTAL TRIAL PRIMARY ENDPOINT OMEROS CORP: SENSITIVITY ANALYSES SUPPORT RESULTS OF PRIMARY ENDPOI...
2025-01-16 22:19
BRIEF-Aligned Data Centers Completes $12+ Billion Capital Raise
Jan 15 (Reuters) - Aligned Data Centers: ALIGNED DATA CENTERS: COMPLETED ROUND OF CAPITAL RAISING TOTALING OVER $5 BILLION OF NEW PRIMARY EQUITY AND OVER $7 BILLION OF NEW DEBT COMMITMENTS ALIGNED DAT...
2025-01-16 01:08
BRIEF-5E Advanced Materials Inc Entered Restructuring Support Agreement
Jan 15 (Reuters) - 5E Advanced Materials Inc FEAM.O: ENTERED RESTRUCTURING SUPPORT AGREEMENT WITH PRIMARY LENDERS & HOLDERS OF CO'S SENIOR SECURED CONVERTIBLE NOTES RSA TO LET LENDERS PURCHASE AGGREGA...
2025-01-15 08:44
